{"id":424,"date":"2021-02-14T22:04:42","date_gmt":"2021-02-14T22:04:42","guid":{"rendered":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/?p=424"},"modified":"2022-07-26T22:05:07","modified_gmt":"2022-07-26T22:05:07","slug":"preclinical-efficacy-of-ribavirin-in-shh-and-group-3-medulloblastoma","status":"publish","type":"post","link":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/2021\/02\/14\/preclinical-efficacy-of-ribavirin-in-shh-and-group-3-medulloblastoma\/","title":{"rendered":"Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma"},"content":{"rendered":"<p>OBJECTIVE Medulloblastoma, the most common pediatric brain malignancy, has Sonic Hedgehog (SHH) and group<\/p>\n<p>3 (Myc driven) subtypes that are associated with the activity of eukaryotic initiation factor 4E (eIF4E), a critical mediator<\/p>\n<p>of translation, and enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and master regulator of transcription.<\/p>\n<p>Recent drug repurposing efforts in multiple solid and hematologic malignancies have demonstrated that eIF4E and<\/p>\n<p>EZH2 are both pharmacologically inhibited by the FDA-approved antiviral drug ribavirin. Given the molecular overlap<\/p>\n<p>between medulloblastoma biology and known ribavirin activity, the authors investigated the preclinical efficacy of repurposing<\/p>\n<p>ribavirin as a targeted therapeutic in cell and animal models of medulloblastoma.<\/p>\n<p>METHODS Multiple in vitro assays were performed using human ONS-76 (a primitive SHH model) and D425 (an aggressive<\/p>\n<p>group 3 model) cells. The impacts of ribavirin on cellular growth, death, migration, and invasion were quantified<\/p>\n<p>using proliferation and Cell Counting Kit-8 (CCK-8) assays, flow cytometry with annexin V (AnnV) staining, scratch<\/p>\n<p>wound assays, and Matrigel invasion chambers, respectively. Survival following daily ribavirin treatment (100 mg\/kg) was<\/p>\n<p>assessed in vivo in immunodeficient mice intracranially implanted with D425 cells.<\/p>\n<p>RESULTS Compared to controls, ribavirin treatment led to a significant reduction in medulloblastoma cell growth<\/p>\n<p>(ONS-76 proliferation assay, p = 0.0001; D425 CCK-8 assay, p &lt; 0.0001) and a significant increase in cell death (flow<\/p>\n<p>cytometry for AnnV, ONS-76, p = 0.0010; D425, p = 0.0284). In ONS-76 cells, compared to controls, ribavirin significantly<\/p>\n<p>decreased cell migration and invasion (Matrigel invasion chamber assay, p = 0.0012). In vivo, ribavirin significantly<\/p>\n<p>extended survival in an aggressive group 3 medulloblastoma mouse model compared to vehicle-treated controls (p =<\/p>\n<p>0.0004).<\/p>\n<p>CONCLUSIONS The authors demonstrate that ribavirin, a clinically used drug known to inhibit eIF4E and EZH2, has<\/p>\n<p>significant antitumor effects in multiple preclinical models of medulloblastoma, including an aggressive group 3 animal<\/p>\n<p>model. Ribavirin may represent a promising targeted therapeutic in medulloblastoma.<\/p>\n<p>(DOI: 10.3171\/2020.8.PEDS20561)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>OBJECTIVE Medulloblastoma, the most common pediatric brain malignancy, has Sonic Hedgehog (SHH) and group 3 (Myc driven) subtypes that are associated with the activity of&hellip;<\/p>\n","protected":false},"author":1,"featured_media":425,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/posts\/424"}],"collection":[{"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/comments?post=424"}],"version-history":[{"count":1,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/posts\/424\/revisions"}],"predecessor-version":[{"id":426,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/posts\/424\/revisions\/426"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/media\/425"}],"wp:attachment":[{"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/media?parent=424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/categories?post=424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.herramientasvirtuales.com\/cienhus\/wp-json\/wp\/v2\/tags?post=424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}